Lyme Vaccine Progress
EMA Validates Pfizer and Valneva's Lyme Vaccine, Initiating European Regulatory Assessment
Key Points
The VALOR trial showed 73.2% efficacy from 28 days after dose four, but the first prespecified analysis did not meet its statistical criterion, adding nuance to the reported efficacy beyond “more than 70%.”
Valneva’s stock jumped about 16.9% after the EMA news, rising to around €2.86 in Paris, underscoring market optimism on European regulatory progress for PF-07307405.
In after-hours trading, Valneva rose nearly 13% and Pfizer edged up about 1.86% to $26.80, illustrating differing but positive investor responses for the companies tied to the candidate.
The vaccine is hexavalent, targeting six OspA serotypes common in North America and Europe, a detail highlighting its broad potential coverage for Lyme disease.
Executives emphasized the public-health potential and scale: Annaliesa Anderson of Pfizer said the team is excited about bringing the first vaccine of its kind to Europe, noting Lyme disease remains a major vector-borne illness, while Valneva’s Thomas Lingelbach cited that more than 200 million people live in Lyme disease risk areas in Europe.
The European Medicines Agency has validated a Marketing Authorization Application for PF-07307405, the Lyme disease vaccine developed by Pfizer and Valneva, officially starting the EU review process, the companies announced. If approved, it would be the first human Lyme disease vaccine ever available in Europe, according to Pharmaphorum.
The news sent Valneva shares up about 16.9% to around €2.86 in Paris, according to Seeking Alpha. In after-hours trading, Valneva rose nearly 13% and Pfizer edged up roughly 1.86% to $26.80, reflecting broad investor optimism about the vaccine's regulatory path forward.
Phase 3 Trial Showed Strong But Nuanced Efficacy
The Phase 3 VALOR trial showed PF-07307405 was 73.2% effective starting 28 days after the fourth dose in people aged five and older, according to Pharmaphorum. The vaccine was well tolerated, with no safety concerns identified. However, the first prespecified analysis did not meet its statistical threshold — adding important nuance to the headline figure of "more than 70%" efficacy.
The vaccine is hexavalent, meaning it targets six variants of outer surface protein A, known as OspA. These six types cover the strains of Lyme-causing bacteria most common in both North America and Europe. That broad coverage is a key part of what makes the candidate stand out from earlier, simpler Lyme vaccine attempts.
200 Million Europeans Live in Lyme Disease Risk Zones
Lyme disease is the world's most common tick-borne illness, according to France 24. Valneva CEO Thomas Lingelbach said that more than 200 million people live in Lyme disease risk areas across Europe alone. That large at-risk population is a central part of the case companies are making to regulators and investors.
Pfizer's Annaliesa Anderson said the team is "excited" about bringing the first vaccine of its kind to Europe. She called Lyme disease a major vector-borne illness and framed the EU application as a key step in the companies' broader global vaccine ambitions, according to BSS News.
Pfizer and Valneva Partnership Traces Back to 2020
The two companies first partnered in 2020 to develop the Lyme vaccine candidate. Under that deal, Pfizer holds exclusive rights to manufacture and sell the vaccine if it wins approval, according to Free Malaysia Today. Valneva, a French-Swiss firm, contributed the scientific foundation for the shot, which is also known as VLA15 and LBV6.
EMA Validation Marks Start, Not End, of EU Review
EMA validation means the agency has confirmed the application is complete enough to begin a formal review. It does not mean the vaccine is approved. The review process typically takes months and involves detailed analysis of clinical trial data, safety results, and manufacturing quality.
Still, the milestone is significant. No Lyme disease vaccine is currently approved anywhere in Europe. Reaching formal EMA review puts PF-07307405 closer than any prior candidate has come to changing that, according to France 24.
Sentiment
Mostly PositivePublishers
11
Articles
47
Reach
58
